United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human FGF-23 ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA
  • Other names:Fibroblast Growth Factor 23, Phosphatonin, Tumor-derived hypophosphatemia-inducing factor, FGF23
  • Species:Human
Cat. No. Size Price


New RBL007R 96 wells (1 kit) $526,55
PubMed Product Details
Technical Data

Type

Sandwich ELISA

Applications

Plasma-EDTA, Urine

Sample Requirements

50 µl/well

Shipping

Shipped on blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

50 - 2000 pg/ml

Limit of Detection

25 pg/ml

Intra-assay (Within-Run)

n = 8
CV = 4.8%

Inter-assay (Run-to-Run)

n = 8
CV = 9.2%

Spiking Recovery

88.0%

Dilution Linearity

107.3%

Summary

Features

It is intended for research use only

The total assay time is less than 20 hours

The kit measures FGF-23

Assay format is 96 wells

Quality Controls are human serum based

Standard is a recombinant protein

Components of the kit are provided ready to use, concentrated or dried

Research topic

Bone and cartilage metabolism, Renal disease

Summary

Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone involved in mineral bone metabolism that helps control phosphate homeostasis and reduces 1,25- dihydroxyvitamin D synthesis. Recent data have highlighted the relevant direct FGF-23 effects on the myocardium, and high plasma levels of FGF-23 have been associated with adverse cardiovascular outcomes in humans, such as heart failure and arrhythmias. Therefore, FGF-23 has emerged as a novel biomarker of cardiovascular risk. experimental data suggest FGF-23 as a direct mediator of cardiac hypertrophy development, cardiac fibrosis and cardiac dysfunction via specific myocardial FGF receptor (FGFR) activation.

Related Products Docs